Topic

Cora Meese is the EVP, director of client services, for Entrée Health.

Articles

As pharmaceutical market access teams head into 2023, these ten trends detail why evolved preparation, thought, and engagement will be needed to meet post-pandemic marketplace expectations. 

10 Market Access Trends to Watch for in 2023

 and can be reached at mhollan@mjhlifesciences.com.

As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.

Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff   

Ira Studin, PhD, MPH, is president of Stellar Managed Care Consulting, a pharma busines strategies firm in Cherry Hill, New Jersey. He has written Strategic Healthcare Management and numerous articles in healthcare business journals. He can be reached at istudin@stellarmc.com

Supporting health plan clinical preparation and financial modeling.

Payer Key Business Factors for Orphan Product Launches

Carolyn Zele is an advisor of solution consulting for MMIT (a Norstella company).

Using market access data from day one of your drug development and commercialization journey puts your brand in the best position to succeed at launch.

How Market Access Can Determine Commercial Success

 and can be reached at fpollaro@mjhlifesciences.com.

Emerging biopharma companies are critical to the vibrancy of the healthcare landscape, but their long road of drug development fails to translate to successful market launch more often than it does for large pharma. What can be done to improve those odds?

Biopharma’s Untapped Value: The Quest to Reverse First-Launch Failure Trends

Webcasts

Webinar Date/Time: Tuesday, Dec 6, 2022, 11am PT | 2pm ET


Expand Marketing Reach and Enhance Commercial Ops With Real-Time Patient Data

Webinar Date/Time: Wednesday, November 30, 2022, 1 pm EDT


How to Leverage Cloud ERP to Support Commercial Readiness

Life sciences professionals will need to keep up with market demand for biologics and biosimilars.

Addressing the Knowledge Gap in Biologics & Biosimilars: Is a Board Certified Biologics and Biosimilars Program the Answer?

Commercial Health Insurance may bring more opportunities for market access in China.

The Emergence of Commercial Health Insurances as an Access Route to the Chinese Market

Different paths to formulary decision-making.